Compare ADMA Biologics Inc (ADMA) vs M&T Bank Corporation (MTB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs M&T Bank Corporation — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while M&T Bank Corporation trades at $233.96 (market cap $35.11B). The key difference: M&T Bank Corporation is far larger — about 16.5× ADMA Biologics Inc's market cap, and M&T Bank Corporation pays a 2.5% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MTB | |
|---|---|---|
Market Cap | $2.13B | $35.11B |
Sector | Health | Financials |
52-Week High | $20.38 | $241.95 |
52-Week Low | $7.60 | $178.63 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MTB trades at $239.75, up 0.36% today, near the consensus price target of $241.56. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $9.63B in 2025, with a strong net income margin of 29.59%. Recent news highlights upcoming Q2 2026 earnings and strategic leadership appointments, reinforcing operational focus.
The outlook is cautiously positive, supported by solid fundamentals and analyst consensus, but risks include elevated investing cash outflows and sensitivity to interest rate changes. The stock presents a value opportunity with a reasonable P/E of 13.47, though investor sentiment remains mixed ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
